Zoster vaccines GRADE assessments

GRADE assessment of zoster vaccines 

GRADE assessment of recombinant herpes zoster vaccine (Shingrix) in:

• immunocompetent older adults compared to placebo
• immunocompetent older adults compared to zoster live vaccine (Zostavax) 
• immunocompromised older adults compared to placebo or unvaccinated

ATAGI recommendations 

• Use of Shingrix versus Zostavax in immunocompetent adults aged ≥50 years
• Use of Shingrix in immunocompromised adults aged ≥18 years
• Use of Shingrix in immunocompetent adults aged ≥50 years

Note

These GRADE documents should be read as a supplement to the Australian Immunisation Handbook (Handbook) recommendations.

• View the Zoster disease chapter in the Handbook here
• View the ATAGI statement on the clinical use of zoster vaccine in older adults in Australia here